نتایج جستجو برای: interferon beta 1

تعداد نتایج: 2915207  

Journal: :Journal of Experimental Medicine 1982

Journal: :Annals of Clinical and Translational Neurology 2014

Journal: :Archives of neurology 2010
Laura F van der Voort Francesca Gilli Antonio Bertolotto Dirk L Knol Bernard M J Uitdehaag Chris H Polman Joep Killestein

OBJECTIVES To confirm that neutralizing antibodies (NAb) to interferon beta can persist after therapy withdrawal and to evaluate whether persisting NAb are associated with a worse clinical disease course in multiple sclerosis (MS). DESIGN Retrospective study. SETTING Tertiary referral center in The Netherlands. PATIENTS A total of 71 patients with relapsing-remitting multiple sclerosis tr...

Journal: :Journal of virology 1988
K Shiroki M Toth

The transcription of endogenous beta interferon mRNA was activated in human embryo kidney (HEK) cells infected with adenovirus type 12 (Ad12) but was activated only inefficiently or not at all in HEK cells infected with Ad5 and rc-1 (Ad5 dl312 containing the Ad12 E1A region). The analysis with Ad12 mutants showed that Ad12 E1B products, especially the 19K protein, were important for the express...

Journal: :Journal of virology 1989
J S Twu R H Schloemer

The manner by which the trans-acting factor encoded by the 1,828-base-pair (bp) BamHI DNA fragment of hepatitis B virus (HBV) suppresses the production of human beta interferon was determined. Steady-state levels of RNA specific for human beta interferon were decreased in cells that contained the 1,828-bp BamHI DNA fragment of HBV. The reduced accumulation of interferon-specific RNA was due to ...

Journal: :Cancer research 1989
D Goldstein S M Bushmeyer P L Witt V C Jordan E C Borden

The combined effects of tamoxifen, a competitive inhibitor of estrogen, and type I or II interferons on the proliferation of several human breast cancer cell lines in vitro were examined. Additive antiproliferative effects were observed with interferons and tamoxifen, in two estrogen receptor positive cell lines, MCF-7 and T-47D. In MCF-7 cells neither beta ser interferon, gamma interferon, nor...

Journal: :Anais brasileiros de dermatologia 2011
Dário Júnior de Freitas Rosa Fernanda de Abreu Toledo Matias Sâmya Diégues Cedrim Ronaldo Figueiredo Machado Alessandra Almeida Montenegro de Sá Vânia Carolina Piccinini Silva

Multiple sclerosis is an inflammatory demyelinating disease of presumed autoimmune origin that affects the central nervous system. The main form of therapy is based on the use of immunomodulators such as interferon beta, which are usually well tolerated. Skin manifestations resulting from treatment with interferon beta-1b consist principally of reactions at the site of subcutaneous application ...

Journal: :The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 2021

Abstract Background The incidence of thyroid dysfunction in multiple sclerosis (MS) patients on interferon (as a disease-modifying line) has been reported many studies performed already therapy. Our study adopted prospective follow-up the profile those newly starting beta therapy over 1 year trying to find correlation between start and occurrence this dysfunction. Objectives To evaluate MS befo...

Journal: :Cell reports 2017
Angel Garcia-Diaz Daniel Sanghoon Shin Blanca Homet Moreno Justin Saco Helena Escuin-Ordinas Gabriel Abril Rodriguez Jesse M Zaretsky Lu Sun Willy Hugo Xiaoyan Wang Giulia Parisi Cristina Puig Saus Davis Y Torrejon Thomas G Graeber Begonya Comin-Anduix Siwen Hu-Lieskovan Robert Damoiseaux Roger S Lo Antoni Ribas

PD-L1 and PD-L2 are ligands for the PD-1 immune inhibiting checkpoint that can be induced in tumors by interferon exposure, leading to immune evasion. This process is important for immunotherapy based on PD-1 blockade. We examined the specific molecules involved in interferon-induced signaling that regulates PD-L1 and PD-L2 expression in melanoma cells. These studies revealed that the interfero...

Journal: :Neurology 2005
Emmanuelle Waubant A Dessa Sadovnick

Many women with multiple sclerosis (MS) ask about the risks of pregnancy before starting (or while on) disease-modifying therapies (DMTs). At least twothirds of patients with MS are women, and the majority are in their childbearing years at the time of clinical onset and diagnosis. DMTs taken during pregnancy could have direct or indirect toxicity (through immunomodulating properties) on pregna...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید